Abstract
Disease caused by cytomegalovirus (CMV) infection can clinically manifest in a variety of ways in the immunodeficient host and lead to significant morbidity and mortality. Infections can be primary, occur as a result of reactivation of latent virus, or infection with a new strain of CMV. Cell-mediated immunity is the main defense against CMV disease. This component of the immune system is frequently affected in children who are born prematurely, have undergone solid organ transplantation or hematopoietic stem cell transplantation, or have infection with human immunodeficiency virus. Accordingly, these children are at increased risk for severe disease due to CMV. In addition, CMV itself alters cell-mediated immunity and may predispose hosts to other bacterial, fungal, or viral infections as well as predispose to graft rejection. The importance of CMV in these special populations of children, emphasizing epidemiology, risk factors, and preventive strategies, is reviewed.
Keywords: Cytomegalovirus, immunocompromised hosts, immunosuppressed, infections, prematurity, transplant, opportunistic, latent virus, stem cell transplantation, seroprevalence, socioeconomic status, symptomatic, suppressor cytotoxic T cells, combining culture
Infectious Disorders - Drug Targets
Title: Cytomegalovirus Infection in Pediatric Immunocompromised Hosts
Volume: 11 Issue: 5
Author(s): Marsha Y. Russell, April Palmer and Marian G. Michaels
Affiliation:
Keywords: Cytomegalovirus, immunocompromised hosts, immunosuppressed, infections, prematurity, transplant, opportunistic, latent virus, stem cell transplantation, seroprevalence, socioeconomic status, symptomatic, suppressor cytotoxic T cells, combining culture
Abstract: Disease caused by cytomegalovirus (CMV) infection can clinically manifest in a variety of ways in the immunodeficient host and lead to significant morbidity and mortality. Infections can be primary, occur as a result of reactivation of latent virus, or infection with a new strain of CMV. Cell-mediated immunity is the main defense against CMV disease. This component of the immune system is frequently affected in children who are born prematurely, have undergone solid organ transplantation or hematopoietic stem cell transplantation, or have infection with human immunodeficiency virus. Accordingly, these children are at increased risk for severe disease due to CMV. In addition, CMV itself alters cell-mediated immunity and may predispose hosts to other bacterial, fungal, or viral infections as well as predispose to graft rejection. The importance of CMV in these special populations of children, emphasizing epidemiology, risk factors, and preventive strategies, is reviewed.
Export Options
About this article
Cite this article as:
Y. Russell Marsha, Palmer April and G. Michaels Marian, Cytomegalovirus Infection in Pediatric Immunocompromised Hosts, Infectious Disorders - Drug Targets 2011; 11 (5) . https://dx.doi.org/10.2174/187152611797636686
DOI https://dx.doi.org/10.2174/187152611797636686 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Runx1/AML1 is a Guardian of Hematopoietic Stem Cells
Current Cancer Therapy Reviews DNA Methyltransferase Inhibitors and their Therapeutic Potential
Current Topics in Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Current Concepts and Future Directions in Radioimmunotherapy
Current Drug Discovery Technologies Meet the Associate Editor
MicroRNA G Protein-Coupled Receptors – Potential Roles in Clinical Pharmacology
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Aberrant Expression of MicroRNAs in B-cell Lymphomas
MicroRNA Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry